Nanoparticulate drug delivery systems composed of amphiphilic block and hyperbranched copolymers
Nanoparticulate drug delivery systems composed of amphiphilic block and hyperbranched copolymers
批准号:
311940-2009
负责人:
Burt, Helen
金额:
$1.46万
依托单位国家:
加拿大
项目类别:
Discovery Grants Program - Individual
财政年份:
2011
资助国家:
加拿大
项目状态:
已结题
起止时间:
2011-01-01 至 2012-12-31
中文摘要
将纳米技术应用于药物,称为“纳米医学”,具有很大的技术和概念突破潜力。纳米药物输送系统的发展将最终使我们能够靶向体内选定的细胞或组织,并控制药物在该部位的释放,从而提高药物的安全性和有效性。该提案的总体目标是开发新型的肿瘤定点纳米颗粒,用于通过化疗药物或热杀死细胞来局部治疗疾病。我们最初的重点将是合成,制备和表征的纳米粒子制成的组织相容性聚合物和负载的抗癌药物,紫杉醇和顺铂,在膀胱癌的潜在应用。大多数患有这种癌症的患者都有浅表疾病,只影响膀胱壁的表面衬里。目前使用直接滴注到膀胱中的药物的化疗治疗不是非常有效,因为药物与膀胱壁的接触时间仅为约2小时,然后发生排尿。我们认为,用组织粘附基团修饰药物纳米颗粒的表面应该延长接触时间,增加药物进入组织的吸收,增加有效性并潜在地减少不必要的副作用。我们已经组建了一个优秀的合作团队,他们将开发例如可以共同递送两种药物的纳米颗粒和具有金涂层的纳米颗粒,这些纳米颗粒可以用特定波长的光照射,并将加热和杀死癌细胞。
英文摘要
The application of nanotechnology to drugs, referred to as "nanomedicines" has a high potential for technological and conceptual breakthroughs. The development of nano-sized drug delivery systems will ultimately allow us to target selected cells or tissues within the body and control the release of drug at that site, resulting in greater safety and effectiveness of the administered drug. The overall goal of this proposal is to develop novel, tumor site-directed nanoparticles for the local treatment of disease with either chemotherapeutic agents or cell-killing by heat. Our initial focus will be the synthesis, preparation and characterization of nanoparticles made of tissue-compatible polymers and loaded with the anticancer drugs, paclitaxel and cisplatin, for potential application in bladder cancer. Most patients with this cancer have superficial disease, affecting just the surface lining of the bladder wall. Current chemotherapy treatments using drugs instilled directly into the bladder are not very effective because the contact time of the drug with the bladder wall is only about 2 hours, before voiding occurs. We believe that modifying the surfaces of the drug nanoparticles with tissue-adhering groups should prolong the contact time, increase uptake of drug into the tissue, increase effectiveness and potentially decrease unwanted side effects. We have assembled an outstanding team of collaborators who will develop, for example, nanoparticles that can co-deliver two drugs and nanoparticles with a gold coating that can be irradiated with light of a certain wavelength and will heat up and kill cancer cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Quantum Materials and Future Technology
-
批准号:CFREF-2014-00005
-
项目类别:Canada First Research Excellence Fund
-
资助金额:$962.48万
-
财政年份:2021
-
负责人:Burt, Helen
-
依托单位:
Quantum Materials and Future Technologies
-
批准号:10009000009-2017
-
项目类别:Canada First Research Excellence Fund
-
资助金额:$475.1万
-
财政年份:2017
-
负责人:Burt, Helen
-
依托单位:
Nanoparticulate drug delivery systems composed of amphiphilic block and hyperbranched copolymers
-
批准号:311940-2009
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$1.46万
-
财政年份:2012
-
负责人:Burt, Helen
-
依托单位:
Nanoparticulate drug delivery systems composed of amphiphilic block and hyperbranched copolymers
-
批准号:311940-2009
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$1.46万
-
财政年份:2010
-
负责人:Burt, Helen
-
依托单位:
Nanoparticulate drug delivery systems composed of amphiphilic block and hyperbranched copolymers
-
批准号:311940-2009
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$1.46万
-
财政年份:2009
-
负责人:Burt, Helen
-
依托单位:
Nanoparticulate drug delivery systems: synthesis and characterization of amphiphilic diblock copolymers
-
批准号:311940-2006
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.51万
-
财政年份:2008
-
负责人:Burt, Helen
-
依托单位:
Nanoparticulate drug delivery systems: synthesis and characterization of amphiphilic diblock copolymers
-
批准号:311940-2006
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.51万
-
财政年份:2007
-
负责人:Burt, Helen
-
依托单位:
Burt Lab/Angiotech Pharmaceuticals partnership
-
批准号:340586-2006
-
项目类别:Synergy Awards
-
资助金额:$1.82万
-
财政年份:2006
-
负责人:Burt, Helen
-
依托单位:
Nanoparticulate drug delivery systems: synthesis and characterization of amphiphilic diblock copolymers
-
批准号:311940-2006
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.51万
-
财政年份:2006
-
负责人:Burt, Helen
-
依托单位:
国内基金
海外基金
登录
查看更多内容
酶响应的中性粒细胞外泌体载药体系在眼眶骨缺损修复中的作用及机制研究
-
批准号:82371102
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:苏蕴
-
依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
-
批准号:82372275
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘耀宝
-
依托单位:
背根神经节中Mrgprd通过一种特异性lncRNA调控阿片类药物耐受的外周机制研究
-
批准号:82371224
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:马柯
-
依托单位:
不同功能基团的电中性Drug-Free纳米颗粒的构建及克服肿瘤耐药的研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:杨胜彩
-
依托单位:
m6A识别蛋白YTHDF2促白血病细胞生长的研究
-
批准号:32070793
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:赵昀
-
依托单位:
泛素结合酶UBE2S调控GPX4/SLC7A11影响肝癌细胞铁死亡的机制研究
-
批准号:32060159
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2020
-
负责人:莫之婧
-
依托单位:
TCF7L2突变介导SMAD7信号轴抑制KRAS突变型结直肠癌转移及耐药的分子机制研究
-
批准号:32000555
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:徐亮
-
依托单位:
PRMT1-meFOXO1通路在低温常压等离子体诱导的三阴型乳腺癌细胞铁死亡中的作用机制研究
-
批准号:31900528
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2019
-
负责人:王真
-
依托单位:
Drug-ADR-Pathway复合网络构建及ADR分子机制研究
-
批准号:61372188
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:陈秀杰
-
依托单位:
IL-6自主分泌介导的B细胞来源淋巴造血系统肿瘤耐药的相关机制研究
-
批准号:81172109
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:柳凤亭
-
依托单位: